Viridian Therapeutics, Inc. (VRDN)
| Previous close | 12.70 |
| Open | 12.73 |
| Bid | 11.94 x 100 |
| Ask | 12.04 x 100 |
| Day's range | 11.80 - 12.73 |
| 52-week range | 10.93 - 28.35 |
| Volume | |
| Avg. volume | 927,601 |
| Market cap | 763.317M |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
WALTHAM, Mass., May 10, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May:
- Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
WALTHAM, Mass., May 08, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ending March 31, 2024.
- Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 03, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 551,000 shares of the company’s common stock to six
